Miraculins announces final results of prostate cancer biomarker study

---

Miraculins Inc., a Canadian biotechnology company dealing with the discovery and validation of cancer biomarkers, announces final results from its PCSC04 study.

The study initiated in November 2006, set out to determine if Miraculins prostate cancer biomarker diagnostic would be able to reduce the number of negative biopsies for patients that had already been screened by the prostate specific antigen (PSA) test and had been referred to a urologist for additional assessment.

The data analyzed showed that the Miraculins urine based test performed with specificity would eliminate approximately 23% of the biopsies for patients who did not have prostate cancer. The test also performed with a sensitivity that correctly identified 93% of patients who were true positives for prostate cancer and needed to be scheduled for a biopsy.

These results were consistent with preliminary results announced by Miraculins on March 19, 2007. Both the test's sensitivity and specificity are expected to improve when an ELISA based test format is fully developed.